Search
News
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
… Therapy in Two Pediatric Leukemias Roswell Park’s Dr. Lisa Niswander presents research results at American Society of … KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD , Assistant Professor of Oncology in the … toxicities and improve long-term remission,” says Dr. Niswander. “Our preclinical studies take a two-pronged …
News
Hyundai Hope On Wheels Awards $100,000 to Roswell Park to Fund Infant Leukemia Immunotherapy Research
Clinical Trial
(AALL2321) A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
Clinical Trial
(AALL2131) An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
News
Roswell Park Experts to Showcase Groundbreaking Hematology Research at 66th ASH Annual Meeting
… is senior author. On Saturday, Dec. 7, at 4:45 p.m., Lisa Niswander, MD, PhD , will present abstract 370, Gliteritinib … is senior author. On Saturday, Dec. 7, at 4:45 p.m., Lisa Niswander, MD, PhD , will present abstract 370, Gliteritinib …